Directors
Director
Dr. Patrick Reynolds, M.D. Ph. D.
- BA in Biology from The University of Texas at Austin
- MD from UT Southwestern Medical School in Dallas, TX
- PhD (Cell Biology) from UT Austin
- Pediatrics training at the National Naval Medical Center Bethesda, MD
- Postdoctoral fellowship was in cancer immunology at UT Southwestern Medical School, Dallas, TX
Research Interests:
- Alternative lengthening of telomeres (ALT) in cancer as a biomarkers and therapeutic targets
- Mechanisms of drug resistance and drugs to modulate resistance in childhood and adult cancers
- Development of novel preclinical testing models for cancer drug development
- Clinical trials testing novel therapeutic approaches for cancer
Dr. Reynolds is the Cancer Center Director for the School of Medicine, Texas Tech University Health Sciences Center (TTUHSC), and is Director of the South Plains Oncology Consortium (SPOC). He is a Professor of Pediatrics, Cell Biology & Biochemistry, and Medicine at the
TTUHSC School of Medicine.
Dr. Reynolds is a member of the neuroblastoma steering committee for the Children's Oncology Group. He has served on multiple grant review study sections and steering committees for the National Cancer Institute. He is a member of the Advisory Committee for Childhood Cancer and the Clinical Trials Advisory Committee for the Cancer Prevention & Research Institute of Texas (CPRIT).
Dr. Reynolds sponsors multiple FDA Investigational New Drug (IND) applications and has active grant support from the National Cancer Institute (NCI), the Department of Defense, and the Cancer Prevention & Research Institute of Texas, and Alex's Lemonade Stand Foundation. His laboratory serves as the Childhood Cancer Repository for the Children's Oncology Group, powered by Alex's Lemonade Stand Foundation. Dr. Reynolds is an author or co-author of more than 250 peer-reviewed scientific papers that have garnered > 30,000 citations.
Associate Director
Min H. Kang, PharmD
- B.S. in Pharmacy from Chungbuk National University, South Korea
- Pharm. D. in Clinical Pharmacy from University of Colorado HSC, Denver, CO
- Post-doctoral fellowship in Molecular and Clinical Pharmacology from the National Cancer Institute, Bethesda, MD
Research Interests:
- Molecular Pathways of MYC activation independent of genomic amplification.
- Development of narciclasine to target upstream of MYC activation.
- Pharmacokinetic and pharmacodynamic characterization of investigational agents.
Dr. Kang is the Cancer Center Associate Director for the School of Medicine, Texas
Tech University Health Sciences Center (TTUHSC). She is the Associate Vice President
for Research at TTUHSC, as well as a Professor of Pediatrics at the TTUHSC School
of Medicine. Her formal training is in clinical and molecular pharmacology and the
conduct of early-phase clinical trials at the National Cancer Institute (NCI). She is the director of a pharmacology resource laboratory that supports the Children’s Oncology Group (COG), South Plains Oncology Consortium, and a number of preclinical therapeutic laboratories. She also directs the TTUHSC
SOM Cancer Center flow cytometry core laboratory. Dr. Kang’s laboratory conducts preclinical
and clinical studies that provide pharmacokinetic, pharmacodynamic, and pharmacogenomic
data in support of multiple phase I, II, and III clinical trials within these consortia.
She has been working in the area of translational research for decades, and preclinical
data from her laboratory have resulted in multiple clinical trials. She also has extensive
experience in formalized preclinical drug testing, having directed the NCI Pediatric
Preclinical Testing Program in vitro testing laboratory for 8 years.
